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Homoharringtonine (HHT) has been widely used in China to treat patients with acute and
chronic myeloid leukemia for decades. Since response to HHT varies among patients, our
study aimed to identify biomarkers that might influence the response to HHT using a
panel of various human lymphoblastoid cell lines (LCLs). Genome-wide association (GWA)
analysis using single nucleotide polymorphism (SNP) and mRNA expression data was
assessed for association with cytotoxicity to HHT in LCLs. Integrated analysis among
SNPs, expression, AUC value was also performed to help select candidate genes for
further functional characterization. Functional validation of candidate genes was performed
using leukemia cell lines (U937, K562). Candidate genes were knocked down using specific
siRNA and its response to HHT was assessed using MTS assay. We found that 15
expression probes were associated with HHT AUC with P < 10−4, and 96 individual
probe sets with P < 10−3. Eighteen SNPs were associated with HHT AUC with P <
10−5 and 281 SNPs with P < 10−4. The integrated analysis identified 4 unique SNPs
that were associated with both expression and AUC. Functional validation using siRNA
knockdown in leukemia cell lines showed that knocking down CCDC88A, CTBP2, SOCS4
genes in U937 and K562 cells significantly altered HHT cytotoxicity. In summary, this study
performed with LCLs can help to identify novel biomarker that might contribute to variation
in response to HHT therapy.
Keywords: genome-wide association study, biomarkers, Homoharringtonine (HHT), lymphoblastoid cell line
system, leukemia
INTRODUCTION
Homoharringtonine (HHT) is a natural cephalotaxus alkaloid
that is derived from the Cephalotaxus species found in China. It
has been widely used in China for the treatment of acute myeloid
leukemia (AML) and chronic myeloid leukemia (CML) for more
than 3 decades. In the United States, the semi-synthesized HHT,
known as Omacetaxine, has been approved by FDA in the setting
of CML after failure of 2 ormore tyrosine kinase inhibitors (TKIs)
(Kantarjian et al., 2013). HHT exhibits its anti-leukemic effects in
myeloid leukemia primarily through inhibition of protein synthe-
sis, cell proliferation and by enhancing apoptosis of leukemic cells
(Zhou et al., 1995; Yinjun et al., 2004; Tang et al., 2006).
Previous studies have shown that HHT has significant syn-
ergistic effects with cytarabine (Zhou et al., 1995). Based on
these observations, investigators in China attempted to add
HHT into the conventional induction therapy (anthracycline
plus cytarabine regimen) in newly diagnosed patients with AML
to improve therapeutic outcomes. A multicenter randomized
controlled phase 3 trial was carried out to assess the efficacy
and safety of HHT-based induction treatment. Results showed
that HHT in combination with cytarabine and aclarubicin
(HAA regimen) or daunorubicin (HAD regimen) improved
both overall complete response (CR) rate and estimated 3-year
overall survival in de novo AML patients under the age of 57
years. However, the addition of HHT also increased early death
rate due to more severe marrow suppression (Jin et al., 2013).
These findings raised a question of when HHT should be used
in AML chemotherapy. If we can find biomarkers that can
predict the response to HHT, then we can decide whether we
should add HHT into conventional regimen. Selection of patients
predicted to respond to HHT would maximize drug efficacy
while minimizing drug-related toxicity.
Several clinical factors may influence drug response; how-
ever, the genetic polymorphism in germline genome can also
play an important role in variation in the response to cancer
therapy (Wang et al., 2011). In recent years, the application of
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high-throughput genomic techniques makes it possible to iden-
tify variation across genome that may help to find biomarkers
responsible for drug sensitivity (Sachidanandam et al., 2001;
Morley et al., 2004; Sabeti et al., 2007). In addition, expres-
sion quantitative trait locus (eQTL) studies performed using
gene expression profiles have identified single nucleotide poly-
morphisms (SNPs) associated with drug response through their
influence on gene expression. The integration of genotype, gene-
expression data as well as drug-induced cytotoxicity or other
pharmacologic phenotypes has been successfully applied in var-
ious previous studies using the same approach described in this
study (Huang et al., 2007; Li et al., 2009).
This study was designed to study the role of genetic variation
in variation in HHT response by using these well-established
pharmacogenomic approaches that involve genome-wide basal
gene expression profiles and genome-wide SNPs for 278 human
lymphoblastoid cell lines (LCLs) to identify SNPs/genes that
might contribute to variation in HHT drug response. This LCL
model system has been successfully used to identify biomarkers
for multiple chemotherapeutic agents in our laboratory (Li et al.,
2008; Niu et al., 2010; Jiang et al., 2013). As described previously,
we have obtained genomic information for these LCLs involving
approximately 1.3 million SNPs per cell line, 54,613 mRNA
expression probe sets. We also have performed genome-wide
imputation using 1000 Genomes Project data in these LCLs. We
next performed a HHT cytotoxicity assay with the same LCLs
to obtain HHT area under the curve (AUC) as an in vitro HHT
response phenotype. After genome-wide association (GWA)
analysis involving single nucleotide polymorphisms (SNPs),
mRNA data and also integrated analysis of SNPs, gene expression
and AUC. The analysis resulted in 7 candidate genes that we
further performed siRNA knockdown to determine their effect
on HHT response or cytotoxicity. Three genes showed significant
impact on HHT cytotoxicity after knocking down with specific
siRNAs.
In summary, we have used genome-wide SNPs and expression
data from a cell line-based model system to identified genes that
were associated with HHT sensitivity. Candidate genes were then
functionally validated by MTS assay. Our goals were to identify
possible biomarkers that might contribute to HHT cytotoxicity.
MATERIALS AND METHODS
CELL LINES
EBV-transformed LCLs from 93 African-American (AA), 91
Caucasian-American (CA), and 94 Han Chinese-American
(HCA) unrelated healthy subjects (sample sets HD 100AA, HD
100 CAU, HD 100 CHI) were purchased from the Coriell Cell
Repository (Camden, NJ, USA) as reported previously (Li et al.,
2008, 2009; Niu et al., 2010; Jiang et al., 2013). All the sam-
ples had been anonymized by the National Institute of General
Medical Sciences (NIGMS) before deposit, and all the sub-
jects had provided written consent for their experimental use.
Human leukemic monocyte cell line U937 and human ery-
thromyeloblastoid leukemia cell line K562 were obtained from
ATCC (U937, ATCC® CRL-1593.2™; K562, ATCC® CCL-243™).
LCLs were cultured in RPMI 1640medium (Mediatech, VA, USA)
FIGURE 1 | Cytotoxicity of Homoharringtonine (HHT). (A) Representative
cytotoxicity dose response curves for HHT. Two cell lines from each of the three
ethnic groups (AA, Africa American; CA, Caucasian American and HC, Han
Chinese American) were selected to illustrate a range of HHT cytotoxicity. The
X-axis indicates the log transformed dosage (nM) and the y-axis indicates the
cell viability normalized to control (without drug treatment). Symbols represent
individual cell line from different ethnic groups. (B) Histograms of frequency
distributions of AUC values for HHT. (C) Race effect on HHT cytotoxicity (AUC
values). Y-axis represents normalized AUC values. (D) Gender effect on HHT
cytotoxicity (AUC values). Y-axis represents normalized AUC values.
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supplemented with 15% heat-inactivated Fetal Bovine Serum
(FBS) (Atlanta Biologicals, GA, USA). K562 cells and U937 cells
were grown in RPMI-1640 medium with 10% FBS.
DRUGS AND CELL PROLIFERATION ASSAY
HHT was purchased from Sigma-Aldrich (St. Louis, MO, USA).
HHT cytotoxicity studies were performed to determine the range
of variation in HHTAUC among the 278 LCL cell lines from three
ethnic groups. Drugs were dissolved in DMSO and were frozen
at −20◦C. Cell proliferation assay were performed in triplicate as
described previously (Li et al., 2008). Briefly, 100µl of LCL cells
or U937 cells (5 × 106 cells/ml) were plated into 96-well plates
(Corning) and were treated with HHT concentration at 0, 2.5, 5,
10, 20, 40, 80, 160, 320 nmol/L. After incubation for 72 h, 20µl
of CellTiter 96® Aqueous MTS Cell Proliferation Assay solution
(Promega Corporation, Madison, WI, USA) was added to each
well. Plates were read in a Safire 2 plate reader (Tecan, AG, USA).
For K562 cells, 100µl of K562 cells (4 × 106 cells/ml) were plated
in 96-well plate and HHT concentration was adjusted to 0, 5, 10,
20, 40, 80, 160, 320, 640 nmol/L. The slight difference in HHT
concentration chosen between K562 and U937 was to derive the
best cytotoxicity curve for each cell line.
FIGURE 2 | Genome-wide association of mRNA expression and SNPs
with HHT cytotoxicity. (A) Association of basal gene expression with HHT
AUC value for 278 LCL cell lines. The y-axis represents the –log10(P-value)
for the association of individual expression array probe sets with HHT AUC,
and the x-axis represents chromosomal location of expression probe sets.
(B) Genome-wide SNPs association with HHT for 278 LCL cell lines. The
y-axis represents the -log10(P-value) for the association of Genome-wide
SNPs with HHT AUC, and the x-axis represents chromosomal location of
SNPs. A P-value of 10−4 is highlighted with a red line.
GENOME-WIDE SNP AND EXPRESSION DATA ANALYSIS
The genotyping and expression array data were obtained for all
278 LCLs and were quality controlled as previously described
(Li et al., 2008; Niu et al., 2010; Jiang et al., 2013). These data
are publicly available from the NCBI Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo) under Super Series accession
numbers GSE24277 and GSE23120. Briefly, DNA from all the
LCLs was genotyped using Illumina HumanHap 550K and 510S
Beadchips, which assayed 561,303 and 487,407 SNPs, respectively.
We also obtained publicly available Affymetrix SNP array 6.0
Chip SNP data involving 906,367 SNPs for the same cells to give
us even better coverage. Quality control (QC) was performed
for all of these SNPs prior to performing statistical analysis.
Specifically, for data obtained with the Illumina 550K array, we
removed 11,258 SNPs that had call rate <95%, 33,237 SNPs
with minor allele frequencies (MAF) <5%, and 49 SNPs that
deviated from Hardy-Weinberg equilibrium (HWE). Therefore,
516,759 Illumina 550K SNPs were used in the genome-wide SNP
analysis. The same approach was used for the QC analysis of
SNPs on the Illumina 510S platform which resulted in a total
of 336,070 SNPs remained for analysis. QC analysis was also
performed for the publicly available Affymetrix 6.0 SNPs. After
removing 32,515 SNPs with call rate <95%, 133,553 SNPs with
MAF <5%, and 324 SNPs that deviated from HWE, a total of
739,395 SNPs remained. After removing redundant SNPs geno-
typed on both Affy and Illumina platforms, 1,366,022 SNPs
obtained from both platforms were available for the GWAS anal-
ysis. Genome-wide imputation was then performed in LCLs.
Specifically, SNPs that were not genotyped but found in themulti-
race (ALL) of the1000 genomes project (11/23/2010 released
version) were imputed by race using BEAGLE v3.3.1 (Browning
and Browning, 2007). SNPs in the 1000 genomes project with
MAF <0.01 were excluded as well SNPs with BEAGLE impu-
tation dosage R2 quality measure <0.3 were excluded from the
further analysis, which resulted in a total of 5,384,559 imputed
markers. Therefore, a total of 6,750,581 SNPs including imputed
and genotyped were used in all the association studies described
below.
For the expression array assays, total RNA was extracted from
each of the cell lines using the RNeasy Mini Kit (QIAGEN Inc.,
Valencia, CA, USA). Total mRNA was assayed after hybridization
to Affymetrix U133 plus 2.0 GenChips as previously described (Li
et al., 2008; Niu et al., 2010). A total of 54,613 probe sets were used
in the analysis.
TRANSIENT TRANSFECTION AND RNA INTERFERENCE
SiRNAs for the candidate genes and negative control siRNA
were purchased from QIAGEN (QIAGEN Inc., Valencia,
CA, USA). 4–5 × 106 cells were transfected with 500 nM of
siRNA using Amaxa™ Cell Line Nucleofector™ transfection
kit (Lonza, Koeln, Germany). After incubation overnight, cells
were plated in 96-well plate for further drug treatment and
MTS assay.
REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION PCR
Total RNA was isolated from cultured cells transfected with
control or specific siRNA with the ZR RNA MiniPrep™ kit
(Zymo Research, Irvine, CA, USA), followed by one-step
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Table 1 | Candidate gene selected for siRNA screening based on GWA analysis.
A. mRNA Exp vs. AUC (PANEL 1)
Gene symbol Chr. Probe id P R* Q**
DST 6 212254-S-at 3.20E–06 0.28 0.14
215016-x-at 5.20E–05 0.24 0.24
212253-x-at 6.19E–05 0.24 0.24
CTBP2 10 201218-at 6.24E–06 −0.27 0.14
210835-s-at 1.39E–05 −0.26 0.16
201220-x-at 5.92E–05 −0.24 0.24
DC88A 2 238759-at 3.71E–05 0.25 0.24
221078_s_at 1.76E–04 0.29 0.23
B. SNP vs. AUC (PANEL 2)
Gene symbol Chr. SNP Position Location MAF*** P R
WDHD1/SOCS4 14 rs1187882 55488747 Intron of WDHD1 5′-upstream of SOCS4 0.15 5.07e–05 0.25
SOCS4/WDHD1 14 rs60805089 55503348 Intron of SOCS4 3′-downstream of WDHD1 0.24 9.73e–05 0.36
SOCS4 14 rs7150145 55508260 Intron 0.24 8.92e–05 0.36
ZNF638 2 rs2058899 71580129 Intron 0.37 6.94e–05 0.24
2 rs17749748 71605145 Intron 0.38 7.70e–05 0.24
2 rs12474072 71636036 Intron 0.38 7.78e–05 0.24
2 rs6714975 71633389 Intron 0.38 9.42e–05 0.24
2 rs4852782 71636240 Intron 0.38 9.42e–05 0.24
2 rs6745907 71609073 Intron 0.38 9.66e–05 0.24
C. INTEGRATED ANALYSIs (PANEL 3)
SNP Genes SNP vs. EXP SNP vs. AUC EXP vs. AUC
SNP Chr. Closest SNP MAF Probe Chr. Gene P R* P R* P R*
gene location id symbol
rs10771093 12 SOX5 Inton 0.214 212253_x_at 6 DST 5.34E-05 0.242 2.37E–05 0.258 3.20E–06 0.278
rs60342295 17 — — 0.119 1566990_x_at 6 ARID1B 9.73E-05 −0.234 3.28E–05 −0.254 0.000811 −0.202
rs4531814 18 ZBTB7C Inton 0.428 231325_at 8 UNC5D 0.00031 −0.217 7.95E–05 0.241 9.80E–06 −0.264
rs58707448 18 — — 0.482 205352_at 3 SERPINI1 0.000138 0.229 4.60E–05 −0.249 6.96E–05 −0.238
*Represents the correlation coefficient R-value for associations.
**Represents the false discovery rate Q-value.
***Represents the minor allele frequency (MAF).
qRT-PCR performed with SYBR® Green PCR Master Mix
Kit (Applied Biosystem, Foster City, CA, USA). Specific
primers for mRNA amplification were purchased from
QIAGEN.
STATISTICAL ANALYSIS
Drug toxicity
The detailed description of analysis methods for accessing the
association of cytotoxicity with SNP and/or mRNA expression
data in these LCL cells has been described previously (Li et al.,
2008; Niu et al., 2010; Jiang et al., 2013). Cytotoxicity phenotypes
were determined by the best fitting curve using the R pack-
age “drc” (dose response curve) (http://cran.r-project.org/web/
packages/drc.pdf) based on a logistic model. The AUC phenotype
was determined using the best fitting curve by numerically deter-
mining the area under the estimated dose-response curve, from
dose 0 to 320 nmol/L.
Association analysis
Partial correlations between: AUC and gene-expression; AUC and
SNPs; and gene expression and SNPs were calculated; adjust-
ing for sex, race, and variables addressing possible population
stratification (sub-race variables). Partial correlations were then
tested using F-tests, with multiple testing being addressed by q-
values which control the false discovery rate (Storey, 2003). To
construct the partial correlations, an adjusted AUC was con-
structed as the standardized residuals from a linear regression of
Van der Waerden transformed AUC values regressed on gender,
race and sub-race variables. Gene expression was first normal-
ized using GCRMA (Ballman et al., 2004; Wu et al., 2004); log2
transformed normalized expression was then likewise regressed
on gender, race and sub-race variables. SNP genotype was mod-
eled as count of rare alleles, then regressed on gender, race
and sub-race variables. Variables addressing possible popula-
tion stratification (sub-race variables) were created from linkage
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disequilibrium thinned genome-wide SNPs using principle com-
ponents analysis within each race (Price et al., 2006). The top 5
principle components were used within each race, thus analyses
were adjusted for labeled cell line race and sub-racial features
within each race (Li et al., 2008; Niu et al., 2010). For siRNA
transfection experiments, group mean value for AUC and gene
expression was compared by using Student’s t-test.
Pathway analysis
For pathway analysis of top associated genes, we used Ingenuity
Pathway Analysis (Ingenuity® Systems, www.ingenuity.com) for
network analysis.
RESULTS
HHT CYTOTOXICITY
HHT cytotoxicity studies were performed to determine the range
of variation in HHT AUC among the 278 individual LCL cell lines
from three ethnic groups. Figure 1A shows representative HHT
cytotoxicity data for a set of cell lines. The frequency distribu-
tion of AUC for HHT was shown in Figure 1B. AUC values did
not show a significant difference among the three racial groups
studied (P = 0.096, Figure 1C). Gender did not have a significant
effect on AUC (P = 0.334, Figure 1D).
CORRELATION BETWEEN EXPRESSION AND AUC
We next performed correlation analysis for the association of
expression array and HHT AUC data to identify genes which
might be associated with HHT cytotoxicity at the gene expres-
sion level (Figure 2A). The association analysis identified 15
expression probe represented 10 annotated genes that were
associated with HHT AUC with P < 10−4, and 96 individ-
ual probe sets represented 79 annotated genes with P < 10−3
(Supplementary Table S1). The most significant probe set for
an annotated gene was DST (P = 3.2 × 10−6). Two other probe
sets of this gene were also associated with HHT AUC (215016-x-
at, P = 5.2 × 10−5; 212253-x-at, P = 6.19 × 10−5). CTBP2 was
found to have three expression probe sets associated with AUC
value (P < 10−4) (201218-at, P = 6.24 × 10−6; 210835-s-at, P =
1.39 × 10−5; 201220-x-at, P = 5.92 × 10−5).
For the functional validation, we chose genes that had
probe sets associated with AUC value with P < 10−4. Among
these genes, we removed genes with low expression levels in
the LCLs (<50 after GCRMA normalization). Therefore, three
genes including DST, CTBP2 and CCDC88A were selected for
further functional studies (Table 1A). Furthermore, we sub-
jected genes that were associated with AUC with P < 10−4
to a pathway based analysis using Ingenuity Pathway anal-
ysis tools. 5 gene signature networks that were significantly
associated with the HHT were obtained (Table 2). The most
significant network consists of 36 molecules or genes in net-
work and 17/36 genes are associated with the functions such
as cellular growth and proliferation, cell death and survival
(Table 2). The IPA network provides graphical representation
of the biological connections between genes as shown in
Figure 4.
Table | 2 Top 5 networks associated with HHT response obtained by Ingenuity pathway analysis.
ID molecules in network Score Focus molecules Top diseases and functions
1 AICDA, AKR1B1, Akt, ANKRD1, BANK1, CASP2, CASP12, caspase,
CBS/LOC102724560, CCDC88A, CD3, Ck2, EBF1, ERK1/2, FADD, IgG1, Igm,
Immun oglobulin, Insulin, Interferon alpha, Jnk, NAP1L1, NFkB (complex), NRF1,
P38 MAPK, PAWR, PPIA, PRDX3, PRKCE, SCD5, SER PINB9, SIRT4, SPRY4,
STX6, TRAF5
36 17 Cellular growth and
proliferation, cell death and
Survival, renal necrosis/cell
death
2 ALG1L2, ATG9A, BRD3, C14orf2, CALM1 (includes others), CEP68, CHD4,
CRYAA/LOC102724652, CTBP1, FAM178A, FXR2, GID8, GIMAP1, GIMAP7,
GJA3, GON4L, HAGHL, ITFG1, LCMT1, MAEA, MAP1LC3B, MKLN1, MRPL44,
MTMR14, OPTN, PPP2R4, PPP2R2B, PTEN, RAB30, RMND5A, SCCPDH,
SMAD9, UBC, WHSC1L1, ZNF143
33 16 Ophthalmic disease,
hereditary disorder, cellular
Assembly and organization
3 APP, ARID1B, BAZ2B, C15orf39, CASP12, CDK3, CLIP4, COL17A1, CTBP2,
CTPS2, DOCK4, DST, ELAVL1, FAM117B, FAM178A, FBXL2, FNDC3B, GATAD2A,
GIMAP5, GIMAP6, IL13, ISCU, KIAA1549, KLF8, MOB1B, NEFH, PLXDC2,
RAB33A, RAI2, RALGPS1, RASSF3, SH3BP5, TWISTNB, UBC, ZBTB20
33 16 Cellular compromise,
neurological disease,
Organismal injury and
abnormalities
4 ACACA, AFF3, AKR1B1, APOBR, BCL3, CASP2, CLCN4, CMC4, COA4, COPS7B,
DDIT3, EPO, FAHD2A, FOXO1, GNS, Hdac, HNF4A, IRF2BP2, ITGA6, KAT2B,
MON1B, NRIP1, NTN1, NUDCD3, OCLN, ONECUT1, PPP1R15A, RASSF1, STK4,
TEX10, TNF, UNC5D, UXT, VASH1, ZBTB45
28 14 Cell death and survival, renal
necrosis/cell death,
Lymphoid tissue structure and
development
5 AChR, Akap9, CDH1, CREB1, DRD2, ERBB2, ESR1, G6PC, GCG, GPATCH2,
HDAC2, IFNG, ITPR1, KIAA2022, LDL, NFKB1, NPY, phosphatase,
PI3K(complex), PIAS1, PIAS3, Pka catalytic subunit, PLAT, POU5F1, PPP1CA,
PPP1R15A, PPP3CB, PRKACA, PTEN, PTPRN, SERPINI1, SHIP,
sphingomyelinase, SYNJ2, VCPIP1
8 5 Cellular compromise,
neurological disease,
Organismal injury and
abnormalities
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FIGURE 3 | Schematic diagram of the strategy for selecting candidate
genes for functional validation. A total of 13 candidate genes were
selected based on genome-wide association of expression (Exp) vs. AUC,
SNP vs. AUC and “Integrated” analysis, as described in the text. After
removing those that were not expressed in our LCLs, 7 genes were further
selected for functional validation.
GENOME-WIDE SNP ASSOCIATION WITH HHT AUC
We performed an analysis of the association of genome-wide
SNPs with HHT AUC (Figure 2B). A total of 561,303 SNPs on
the Illumina 550K SNP array and 487,044 SNPs on the Illumina
510S SNP array had been genotyped using DNA from each of
these 278 cell lines. We also had access to publicly available
Affymetrix 6.0 SNP array data. After quality control and genome
wide imputation, a total of 6,750,581 SNPs were used in the
association studies.
GWAS was performed between SNPs and HHT AUC values.
Although none of the SNPs reached genome-wide significance
(P < 10−8), 18 SNPs had P < 10−5 and 281 SNPs had P < 10−4
(Supplementary Table S2). The P value for the most significant
SNPs (rs1250991) was 3.1 × 10−7.
For functional validation, we identified 15 regions/loci that
contained at least two SNPs with P < 10−4 within 50 kb in each
of these regions (a total of 95 SNPs). We defined these regions as
“SNP peak region.” From these regions, we picked up three genes
which were also expressed in LCLs and leukemia cells for further
analysis (Table 1B).
INTEGRATED ANALYSIS
The effect of genetic variation on HHT-induced cytotoxicity
might result in part from the regulation of gene expression.
Therefore, we performed an integrated analysis that included data
from SNPs, basal expression, and HHT AUC, as reported before
(Li et al., 2009; Niu et al., 2010; Jiang et al., 2013).
Specifically, for the top HHT associated SNPs, (i.e., SNP with
P < 10−4), we determined their association with gene expression
using P< 10−4 as a cutoff. These SNP–associated genes were then
narrowed down to those whose mRNA gene expression probe sets
that were also associated with HHT cytotoxicity (P < 10−3). We
used the less stringent criteria to capturemore potential candidate
genes for further functional validation. Through this integrated
analysis, we identified 4 unique SNPs that were associated with
expression and AUC (Table 1C). None of the SNPs were in cis-
regulatory region.
FUNCTIONAL VALIDATION OF CANDIDATE GENES IN HUMAN
LEUKEMIA CELLS
In summary, we selected 7 genes based on the strategy shown
in Figure 3 to perform further functional validation in human
leukemia cell lines: U937 and K562. Since HHT is commonly
used in the patients of AML and CML, leukemic monocyte cell
line U937 and human erythromyeloblastoid leukemia cell line
K562 cells were used for further studies. These functional experi-
ments involved siRNA knockdown, followed byMTS cytotoxicity.
Knocking down CCDC88A, CTBP2, and SOCS4 genes exhibited
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FIGURE 4 | Gene network analysis of top HHT associated genes. Ingenuity pathway analysis was performed. Each node in the network represents a gene
and edge represents a relationship, the pink colored nodes in the network are the significant genes that are correlated with HHT AUC phenotype.
significant resistance to HHT sensitivity in U937 and K562 cells
(Figure 5). The others did not show significantly impact on HHT
sensitivity.
Taken together, through the initial screening studies in LCLs
and further functional validation in leukemia cell lines, we
found that the expression of three genes, CCDC88A, CTBP2, and
SOCS4, were involved in HHT-induced response.
DISCUSSION
HHT is a commonly used drug for the treatment of acute and
chronic myeloid leukemia in China. Recently it has also been
approved by FDA for the treatment of CML resistant to TKIs.
The addition of HHT improved both CR rate and Relapse Free
Survival (RFS) rate. However, its major dose-limiting toxicity is
bone marrow suppression. The response to HHT varied widely
as some patients showed no response whereas the bone-marrow
suppression was severe. Therefore, a better understanding of the
biology underlying the variation to HHT could help us maximize
HHT efficacy while minimizing drug related toxicity.
Recent studies have raised the possibility that genetic variation
might contribute to individual variation in drug response. Many
pharmacogenomic studies have successfully used LCL models to
illustrate the contribution of germline genetic variations to vari-
ation in chemotherapeutic drug response. For example, using the
LCL system, previous findings have identified potential biomark-
ers for response to a series of drugs including Ara-C, 5-FU,
Asparaginase, Daunorubicin (Watters et al., 2004; Huang et al.,
2007; Peters et al., 2009; Chen et al., 2011). In some cases, find-
ings from the LCLs were further validated in clinical studies.
FKBP5, which was found as a biomarker of Ara-C response using
the LCL system, was further studied at mechanistic levels show-
ing that FKBP5 promoted the dephosphorylation of AKT and
downregulated the AKT activity, which in turn, increased cyto-
toxicity by triggering apoptosis in the presence of Ara-C (Pei et al.,
2009). These findings were validated in a clinical study, in which
SNPs within FKBP5 were genotyped in a cohort of 187 pedi-
atric acute myeloid leukemia patients treated with Ara-C. Two
of the SNPs were associated with both event-free and overall
www.frontiersin.org January 2015 | Volume 5 | Article 465 | 7
Tong et al. GWAS for identification of biomarkers for Homoharringtonine
FIGURE 5 | SiRNA screening of candidate genes by MTS assay in
leukemia cell lines. Data are shown for 3 of the 7 candidate genes that were
studied in U937, K562 leukemia cell lines by MTS assay after siRNA
knockdown. Experiments were repeated in triplicate with at least two
independent experiments. Error bars indicate standard error of the mean
(SEM) values. Significance was defined by P-values. (A) knockdown
efficiency was determined by qRT-PCR. The y-axis indicates relative gene
expression after siRNA knockdown when compared with negative control
siRNA. (B) MTS assays. The x-axis indicates the log transformed HHT dose,
and the y-axis indicates the surviving fraction after exposure to HHT.
survival (Mitra et al., 2011). Based on the potential impact of
these findings in individualizing chemotherapy, we aimed to use
this well-established LCLs model to find biomarkers responsible
for HHT cytotoxicity.
In the present study, we performed a genome-wide association
analysis using 278 LCLs for which we had 1.3 million SNPs, basal
gene expression data, and HHT cytotoxicity AUC phenotype to
identify genes which might be responsible for HHT sensitivity.
Based on these data, our study identified top HHT cytotoxic-
ity associated gene networks (Figure 4 and Table 2) that might
help generate hypothesis as well as yield a total of 7 genes which
were also expressed in LCLs and leukemia cell lines for further
studies. The LCL system used in our screening studies has limita-
tions. EBV transformation might cause chromosomal instability
and the cellular changes in LCLs (Sie et al., 2009), and other fac-
tors such as cell growth rate and ATP level can also have effect on
cytotoxicity (Choy et al., 2008). Since these LCL cell lines may not
represent the response of leukemia cell lines to HHT, we identified
7 top candidate genes to perform functional validation studies
using siRNA knockdown in two leukemia cell lines: U937 and
K562 cells. U937 cells lines are derived from leukemic monocyte
cells and K562 cells are also one of myelogenous leukemia cell
lines. These two cell lines, tended to show similar results for the
three genes (CCDC88A, CTBP2, SOCS4) tested. Our results sug-
gested that knockdown of these genes made cells more resistant
to HHT.
CCDC88A, also named as Coiled-Coil Domain Containing
88A, encodes amember of the Girdin family of coiled-coil domain
containing proteins. The encoded protein enhances Akt signaling
by mediating phosphoinositide 3-kinase (PI3K)-dependent acti-
vation of Akt. AKT activation regulates DNA replication and cell
proliferation by phosphorylating the downstream effectors GSK3
and FOXO1/FKHR. The PI3K/AKT and mTOR signaling path-
ways are activated in acute myeloid leukemia (Park et al., 2010).
Although the mechanism responsible for CCDC88A involve-
ment in HHT response is unclear, given the roles of AKT in the
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development of leukemia, it was not surprising that this gene
might play a role in variable response to HHT. However, we rec-
ognized that the CCDC88A had a positive association with HHT
cytotoxicity in LCLs, while our knockdown showed the opposite
effect, which might be due to the difference between LCLs and
Leukemia cell lines. Further mechanistic studies will be needed
to confirm the results. The protein encoded by SOCS4 belongs
to the suppressor of cytokine signaling (SOCS), also known as
STAT-induced STAT inhibitor (SSI), protein family. SOCS family
members are known to be cytokine-inducible negative regulators
of cytokine signaling, including JAK1/STAT3 pathway. SOCS4
has been also demonstrated to regulate EGFR signaling in vitro
(Chan et al., 2009). Therefore, regulation of both pathways could
contribute to HHT cytotoxicity. CTBP2 gene produces alterna-
tive transcripts encoding two distinct proteins. One protein is
a transcriptional repressor, while the other isoform is a major
component of specialized synapses known as synaptic ribbons.
Transcription corepressor CTBP2 has been reported to directly
bind acinus, which is regulated by NGF (nerve growth fac-
tor), inhibiting its stimulatory effect on cyclin A1 expression in
leukemia (Trengove and Ward, 2013). Although there is limited
information with regard to the involvement of these genes to
HHT response, our results suggest a possible role for their rela-
tionship with variation in HHT response. Further mechanistic
studies of these genes as well as additional association studies in
patients treated with HHT are needed to validate the genes as
biomarkers of HHT response.
CONCLUSIONS
In summary, we used a pharmacogenomics approach based on
the use of genomic data rich LCLs system to identify genetic
candidate that might contribute to HHT cytotoxicity. Functional
validation of these candidate genes may further support the fea-
sibility of utilizing these genes for clinical validation of HHT
response. These results may enhance our ability to individualized
treatment with HHT.
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